Jair Pinheiro

Ms. Jair Pinheiro

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2023 in Jornal Brasileiro de Pneumologia
Verified
Journal Article
Open access
RLRafaela Borge Loureiro
Rafaela Borge Loureiro
LGLeticia Molino Guidoni
Leticia Molino Guidoni
GFGeisa Carlesso Fregona
Geisa Carlesso Fregona
SOSandra M.V.L. DE OLIVEIRA
Sandra M.V.L. DE OLIVEIRA
DSDaniel Souza Sacramento
Daniel Souza Sacramento
EMEthel Maciel
Ethel Maciel
Objective: To evaluate the implications of the proportion of annual family income spent in the pre- and post-diagnosis periods in tuberculosis patients followed for after at least one year after completing tuberculosis treatment in Brazil. Methods: This was a cross-sectional study of tuberculosis patients followed for at least one year after completing tuberculosis treatment in five Brazilian capitals (one in each region of the country). Results: A total of 62 patients were included in the analysis. The overall average cost of tuberculosis was 283.84 Brazilian reals (R$) in the pre-diagnosis period and R$4,161.86 in the post-diagnosis period. After the costs of tuberculosis disease, 71% of the patients became unemployed, with an overall increase in unemployment; in addition, the number of patients living in nonpoverty decreased by 5%, the number of patients living in poverty increased by 6%, and the number of patients living in extreme poverty increased by 5%. The largest proportion of annual household income to cover the total costs of tuberculosis was for the extremely poor (i.e., 40.37% vs. 11.43% for the less poor). Conclusions: Policies to mitigate catastrophic costs should include interventions planned by the health care system and social protection measures for tuberculosis patients with lower incomes in order to eliminate the global tuberculosis epidemic by 2035-a WHO goal in line with the United Nations Sustainable Development Goals.

2 September 2020 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
MCMarcelo Cordeiro-Santos
Marcelo Cordeiro-Santos
JPJair Pinheiro
Jair Pinheiro
RSRenata Spener-Gomes
Renata Spener-Gomes
ASAlexandra Brito de Souza
Alexandra Brito de Souza
MRMaria Gabriela de Almeida Rodrigues
Maria Gabriela de Almeida Rodrigues
ATAnete Trajman
Anete Trajman
GeneXpert® Edge (GX-Edge) is a new point-of-care platform not yet tested in the field. In this proof-of-concept study conducted for the diagnosis of tuberculosis in communities living alongside two large rivers of the Brazilian Amazon, we demonstrate that GX-Edge implemented in boats to offer onsite testing is a feasible strategy to investigate potentially devastating diseases such as tuberculosis in difficult-to-reach populations, such as riverside communities.

9 August 2024 in Microorganisms
Verified
Journal Article
Open access
PDF file
YAYan Mathias Alves
Yan Mathias Alves
TBThaís Zamboni Berra
Thaís Zamboni Berra
SJSonia Jezus
Sonia Jezus
VAVânia Maria Silva Araújo
Vânia Maria Silva Araújo
JPJair Pinheiro
Jair Pinheiro
RARicardo Alexandre Alexandre Arcencio
Ricardo Alexandre Alexandre Arcencio
Migration, a multifaceted phenomenon, has a significant impact on health. Migrants perform similar movement patterns within their country of origin, in transit, and in the country of destination, thus making it difficult to monitor TB treatment throughout the journey. The objective was to compare the effectiveness of different treatment modalities in adherence to the short-term regimen for LTBI (3HP) among international migrants and refugees. This is a quasi-experimental study conducted in Manaus-AM. The study population was made up of international migrants. The certification and monitoring of medication intake employed three strategies: self-administration (SA), directly observed conventional therapy (DOT), and Video Telemonitoring System for Tuberculosis Treatment (VDOT). The VDOT group and SA group exhibited the lowest rate of treatment dropout or interruption at 16.1%, followed by the DOT group at 23.1%. The results suggest that the most effective strategy for ensuring adherence among migrants and refugees was VDOT (OR_adj 0.26; CI 0.7–0.94), suggesting that migrants may be more likely to adhere to and complete their treatment. The results show that relying on different treatment strategies, adapted to the individuals’ needs and risk factors, is a viable and effective way of providing person-centered TB care.

16 December 2025 in PLOS Global Public Health
Verified
Journal Article
Open access
MPMariana Cristina Campos Falleiros Pires
Mariana Cristina Campos Falleiros Pires
YLYiran E. Liu
Yiran E. Liu
ELEverton Ferreira Lemos
Everton Ferreira Lemos
LSLiliane Ferreira da Silva
Liliane Ferreira da Silva
MCMariana Garcia Croda
Mariana Garcia Croda
JCJulio Croda
Julio Croda
Several tuberculosis (TB) vaccine candidates are currently advancing to late-stage clinical trials. Prisons in low-and middle-income countries harbor some of the highest rates of TB in the world, making persons deprived of liberty (PDL) an important population to prioritize for the introduction of effective vaccines. However, the inclusion in clinical trials raises significant ethical concerns due to a history of exploitation and mistreatment within medical research. To date, PDL own perspectives on participating in vaccine research have been largely overlooked. This multicenter qualitative study employed focus group (FG) discussions in seven state prisons across four of the five regions of Brazil, involving 91 incarcerated individuals (64 men and 27 female) between February and August 2024. The discussions explored participants’ perceptions regarding health in prisons, TB, vaccines in general, new TB vaccines, and their potential participation in research. Participants reported encountering difficulties in accessing healthcare services within the prison system and shared personal or indirect experiences with TB, as well as concerns about their family members being at risk for TB exposure. While they generally held positive perceptions about vaccines and trials, they emphasized the need for clear and transparent information, respect for individual autonomy, and assurances of accountability from researchers as conditions of their willingness to participate in future trials. PDL perceptions regarding participation in clinical trials for new TB vaccines are significantly influenced by their prior experiences with the prison health system and their level of trust in research institutions. To ethically and effectively include PDL in future research, it is crucial to prioritize respect for autonomy and transparent communication about the risks and potential benefits involved.

1 January 2026 in Revista da Sociedade Brasileira de Medicina Tropical
Verified
Journal Article
Open access
JPJair Pinheiro
Jair Pinheiro
LALara Bezerra de Oliveira Assis
Lara Bezerra de Oliveira Assis
DBDjane Baia
Djane Baia
VOVitória Celestino Oliveira
Vitória Celestino Oliveira
LGLeandro Sousa Garcia
Leandro Sousa Garcia
MCMarcelo Cordeiro-Santos
Marcelo Cordeiro-Santos
Background: Tuberculosis (TB) remains a major public health challenge in Brazil, particularly in the state of Amazonas, where geographic, socioeconomic, and health system barriers hinder the implementation of TB preventive treatment (TPT). This study describes the scale-up of TPT, supported by integrated actions across surveillance, health services, and academia in this high-burden setting. Methods: We conducted a retrospective implementation analysis of TPT in Amazonas, Brazil (2016-2024), using data from the IL-TB system, SINAN-TB, and HIV/AIDS Clinical Monitoring Panel. A structured set of indicators was used to assess TPT delivery, decentralization, diagnostic practices, regimen uptake, and treatment outcomes. Proportions and rates were estimated with 95% confidence intervals (95% CI). Results: A total of 8,120 individuals initiated TPT, including 5,001 TB contacts, whereas more than 70,000 contacts were recorded in the SINAN-TB. Following the IL-TB implementation in 2019, the indicators showed a sustained expansion of TPT delivery. By 2024, TPT initiation among contacts reached 18.4% (95% CI: 17.6-19.3), and 959 PLHIV initiated TPT, corresponding to 441.33 per 1,000 antiretroviral therapy. The proportion of TPT initiation in primary health care increased from 19.3% (95% CI: 13.8-26.4) in 2018 to 55.2% (95% CI: 53.3-57.1) in 2024. Use of 3HP (weekly rifapentine plus isoniazid for three months) rose from 12.7% (95% CI: 10.6-15.1) in 2021 to 93.3% (95% CI: 92.3-94.2) in 2024. Completion reached 84.8% (95% CI: 82.9-86.6) and remained above 80% thereafter. Conclusions: TPT scale-up in Amazonas was accompanied by expanded access, greater decentralization, and rapid adoption of shortened regimens, although important coverage gaps among priority populations remain.

6 July 2025 in medRxiv
Verified
Preprint
Open access
PDF file
MPMariana Cristina Campos Falleiros Pires
Mariana Cristina Campos Falleiros Pires
YLYiran E Liu
Yiran E Liu
ELEverton Ferreira Lemos
Everton Ferreira Lemos
LSLiliane Ferreira da Silva
Liliane Ferreira da Silva
MCMariana Garcia Croda
Mariana Garcia Croda
JCJulio Croda
Julio Croda
Background Several tuberculosis (TB) vaccine candidates are currently advancing to late stage clinical trials. Prisons in low- and middle-income countries harbor some of the highest rates of TB in the world, making persons deprived of liberty (PDL) an important population to prioritize for the introduction of effective vaccines. However, their inclusion in clinical trials raises significant ethical concerns due to a history of exploitation and mistreatment within medical research. To date, PDL’s own perspectives on participating in vaccine research have been largely overlooked. This study aimed to understand the perceptions of PDL regarding TB, vaccines, and their potential participation in clinical trials of new TB vaccines. Methods This multicenter qualitative study employed focus group (FG) discussions in seven state prisons across four of the five regions of Brazil, involving 91 incarcerated individuals (64 men and 27 women). Participants were selected through convenience sampling and interviewed between February and August 2024. The FGs followed a standardized structure, exploring participants' perceptions regarding health in prisons, TB, vaccines in general, new TB vaccines, and their potential participation in research. The discussions were transcribed verbatim and analyzed using thematic content analysis. Results Participants reported encountering difficulties in accessing healthcare services within the prison system. They also shared personal or indirect experiences with TB, as well concerns about their family members being at risk for tuberculosis exposure. While participants generally held positive perceptions about vaccines and vaccine trials, they emphasized the need for clear and transparent information, respect for individual autonomy, and assurances of accountability from researchers as conditions of their willingness to participate in future TB vaccine trials. Conclusions PDL perceptions regarding participation in clinical trials for new TB vaccines are significantly influenced by their prior experiences with the prison health system and their level of trust in research institutions. To ethically and effectively include PDL in future research, it is crucial to prioritize respect for participant autonomy and transparent communication about the risks and potential benefits involved.